Grant of Share Options - replacement

Renalytix PLC

01 March 2024

 

The following amendment has been made to the ' Grant of Share Options' announcement released on 23 November 2023 at 07:00 under RNS No 3917U.

The sentence "All the Share Options granted one twelfth of the Share Options vest 3 months from the date of grant with one twelfth vesting quarterly after that, subject to the individuals remaining employed by the Company as Non-Executive Directors" has been removed and replaced with "The share option grant would vest 100% in 12 months from date of grant".

All other details remain unchanged.

The full amended text is shown below.

Renalytix plc

("Renalytix" or the "Company")

Grant of Share Options

LONDON and SALT LAKE CITY - November 23, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that the Board have granted options over a total of 380,000 ordinary shares of 0.25 pence each in the capital of the Company (the "Share Options") to the following individuals:

Name	Position	Options granted
Christopher Mills	Non-Executive Chairman	95,000
Daniel Levangie	Non-Executive Director	95,000
Chirag Parikh	Non-Executive Director	95,000
Catherine Coste	Non-Executive Director	95,000

The Share Options, which have been issued in line with the Company's existing share option plan, have an exercise price of £0.245 per ordinary share, being the closing price of the shares on the 17 November 2023.  

The share option grant would vest 100% in 12 months from date of grant.

The issue of the Share Options are deemed to be related party transactions pursuant to AIM Rule 13 of the AIM Rules for Companies. The Company's directors (excluding those who are being awarded the Share Options) consider, having consulted with the Nominated Adviser, Stifel Nicolaus Europe Limited, that the terms of the related party transactions are fair and reasonable insofar as the shareholders of the Company are concerned.

For further information, please contact:

Renalytix plc	www.renalytix.com
James McCullough, CEO	Via Walbrook PR
Stifel (Nominated Adviser, Joint Broker)	Tel: [phone]
Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea
Investec Bank plc (Joint Broker)	Tel: [phone]
Gary Clarence / Shalin Bhamra
Walbrook PR Limited	Tel: [phone] or [e-mail]
Paul McManus / Alice Woodings	Mob: [phone]
CapComm Partners
Peter DeNardo	Tel: [phone] or [e-mail]

About Renalytix

About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Christopher Mills
2	Reason for the notification
a)	Position/status	Non-Executive Chairman
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Renalytix plc
b)	LEI	213800NTOH3FK3WER551
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Options over ordinary shares of 0.25 pence each in the Company
	Identification code	GB00BYWL4Y04
b)	Nature of the transaction	Grant of options over shares
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			£0.245	95,000
d)	Aggregated information
	- Aggregated volume	95,000
	- Price	£23,275
e)	Date of the transaction	21 November 2023
f)	Place of the transaction	Outside of trading venue - off market

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Dan Levangie
2	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Renalytix plc
b)	LEI	213800NTOH3FK3WER551
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Options over ordinary shares of 0.25 pence each in the Company
	Identification code	GB00BYWL4Y04
b)	Nature of the transaction	Grant of options over shares
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			£0.245	95,000
d)	Aggregated information
	- Aggregated volume	95,000
	- Price	£23,275
e)	Date of the transaction	21 November 2023
f)	Place of the transaction	Outside of trading venue - off market

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Chirag Parikh
2	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Renalytix plc
b)	LEI	213800NTOH3FK3WER551
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Options over ordinary shares of 0.25 pence each in the Company
	Identification code	GB00BYWL4Y04
b)	Nature of the transaction	Grant of options over shares
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			£0.245	95,000
d)	Aggregated information
	- Aggregated volume	95,000
	- Price	£23,275
e)	Date of the transaction	21 November 2023
f)	Place of the transaction	Outside of trading venue - off market

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Catherine Coste
2	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Renalytix plc
b)	LEI	213800NTOH3FK3WER551
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Options over ordinary shares of 0.25 pence each in the Company
	Identification code	GB00BYWL4Y04
b)	Nature of the transaction	Grant of options over shares
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			£0.245	95,000
d)	Aggregated information
	- Aggregated volume	95,000
	- Price	£23,275
e)	Date of the transaction	21 November 2023
f)	Place of the transaction	Outside of trading venue - off market

 

END